Breaking
Saturday, June 27, 2026

Mergers & Acquisitions Analysis

🇺🇸 FDA

Expert commentary and market intelligence for pharma strategy teams

Showing 1–12 of 55 articles

High impact AnalysisJun 7, 2026

AbbVie Cerevel acquisition closes in $8.7B neuroscience deal

immunology · 6 min

Dr. Sarah Mitchell
Critical impact AnalysisJun 7, 2026

Eli Lilly pipeline and deals: GLP-1, vaccines, and 2026 outlook

diabetes · 7 min

Dr. Sarah Mitchell
High impact AnalysisJun 7, 2026

AbbVie closes $8.7B Cerevel deal as neuroscience pipeline expands

U.S. Federal Trade Commission · immunology · 5 min

Dr. Sarah Mitchell
High impact AnalysisJun 6, 2026

McGuireWoods' Alyssa Campbell Honored in M&A Advisor Emerging Leaders Awards

5 min

Dr. Sarah Mitchell
High impact AnalysisJun 6, 2026

EU Draft Merger Guidelines: Capabilities Treatment Needs Revisiting

European Commission · 5 min

Dr. Sarah Mitchell
High impact AnalysisJun 6, 2026

Weekly Buzz: PHG, KMDA Win FDA Nod; FULC Halts Pociredir; RMD Closes Noctrix Deal; NVS Paces In IgAN

FDA · IgAN · 6 min

Dr. Sarah Mitchell
High impact AnalysisJun 5, 2026

Otsuka kidney drug data and Pfizer AI deal: Biopharma deal tracker

IgA nephropathy · 8 min

Dr. Sarah Mitchell
High impact AnalysisJun 5, 2026

Kairos Pharma Highlights CL-741 Acquisition and 2026 Clinical Milestones: A Strategic Analysis for Pharma Decision-Makers

oncology · 5 min

Dr. Sarah Mitchell
High impact AnalysisJun 5, 2026

China: The Innovation Factor – Implications for Pharma BD and Investors

6 min

Dr. Sarah Mitchell
High impact AnalysisJun 4, 2026

Utah Medical Board Scolded for Going Rogue with AI Criticism: Deal Implications for Pharma

6 min

Dr. Sarah Mitchell
High impact AnalysisJun 4, 2026

SGS Expands Bioanalytical Testing Capabilities in North America with Acquisition of CMIC, INC.

4 min

Dr. Sarah Mitchell
High impact AnalysisJun 4, 2026

Mercury Acquires King Courier to Grow Bay Area Logistics: Deal Intelligence for Pharma Teams

5 min

Dr. Sarah Mitchell